EGFR Inhibitors Market Poised for 7.9% CAGR Growth Through 2036, Driven by Next-Generation TKIs, ADCs, and Bispecific Antibodies
核心洞察
The global EGFR (搜索) inhibitors market reached USD 7 billion in 2025 across the 7MM, with the United States accounting for approximately 60% of total market share.
A wave of emerging therapies including zipalertinib, firmonertinib (搜索), ivonescimab, and multiple ADC candidates is expected to reshape the treatment landscape for EGFR (搜索)-mutated cancers.
The FDA has set PDUFA action dates for ivonescimab (November 14, 2026) and zipalertinib (February 27, 2027), signaling imminent regulatory decisions for two novel agents.
The global market for epidermal growth factor receptor (EGFR (搜索)) inhibitors is projected to experience significant expansion, growing at a compound annual growth rate (CAGR) of 7.9% during the forecast period from 2026 to 2036, according to a comprehensive market analysis released by DelveInsight (搜索). The market, valued at USD 7 billion across the seven major markets (7MM: US, EU4, UK, and Japan) in 2025, is being propelled by the entry of next-generation tyrosine kinase inhibitors (TKIs), antibody-drug conjugates (ADCs), and innovative combination strategies with immunotherapy.
The United States dominated the EGFR (搜索) inhibitor treatment landscape in 2025, representing approximately 60% of the total market across the 7MM, compared to other major markets including Germany, France, Italy, Spain, the United Kingdom, and Japan. In the same year, the 7MM had approximately 330,000 incident cases eligible for EGFR inhibitor therapy.
A Shifting Therapeutic Paradigm
Treatment approaches for EGFR (搜索)-mutated non-small cell lung cancer (搜索) (NSCLC) have advanced considerably over the past two decades. First-generation agents such as erlotinib and gefitinib, followed by second-generation therapies including afatinib and dacomitinib, and subsequently the third-generation TKI osimertinib, have consistently demonstrated improved clinical outcomes over conventional chemotherapy in terms of response rates and survival. Osimertinib continues to serve as the global standard of care for EGFR-mutant NSCLC, supported by robust progression-free survival and overall survival benefits along with extensive regulatory approvals across multiple disease stages.
However, the competitive landscape is intensifying. Amivantamab is emerging as a strong competitor, broadening its role beyond EGFR (搜索) exon 20 insertion mutations through combination approaches involving lazertinib and chemotherapy. In February 2026, the FDA approved once-monthly RYBREVANT FASPRO plus LAZCLUZE for first-line EGFR-mutated advanced NSCLC, further solidifying this combination's position in the market.
Exon 20 Insertion: The New Battleground
EGFR (搜索) exon 20 insertion-positive NSCLC remains particularly challenging to manage with conventional TKIs. Following the withdrawal of mobocertinib, amivantamab became the primary approved therapeutic option in this segment. However, the approval of sunvozertinib in 2025 has intensified competition, while additional TKIs such as firmonertinib (搜索) and zipalertinib continue to advance through clinical development.
Aparna Thakur, an oncology expert at DelveInsight (搜索), noted that "Exon 20 insertion has emerged as a key competitive arena, with the approvals of RYBREVANT and ZEGFROVY creating a new market segment, while several late-stage candidates, including furmonertinib and zipalertinib, are further heightening the competitive landscape."
Emerging Therapies and Regulatory Milestones
Several high-profile regulatory submissions are reshaping the near-term outlook. In January 2026, the US FDA accepted Summit Therapeutics' Biologics License Application for ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, supported by findings from the Phase III HARMONi trial. The FDA set a PDUFA action date of November 14, 2026. Developed using Akeso Biopharma (搜索)'s proprietary Tetrabody platform, ivonescimab is designed to simultaneously inhibit PD-1 interactions with PD-L1 and PD-L2 while blocking VEGF from binding to its receptors.
In April 2026, Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced FDA acceptance of the New Drug Application for zipalertinib, a next-generation irreversible oral EGFR (搜索) inhibitor specifically developed to selectively target tumors carrying EGFR exon 20 insertion mutations while sparing wild-type EGFR activity. The application, covering patients with locally advanced or metastatic NSCLC whose disease progressed after platinum-based chemotherapy with or without prior amivantamab treatment, received a PDUFA target date of February 27, 2027.
ArriVent BioPharma and Shanghai Allist Pharmaceuticals' firmonertinib (搜索), an orally administered mutation-selective EGFR (搜索) inhibitor with strong CNS penetration, is being investigated in the global Phase III FURVENT trial as a first-line option for NSCLC patients with EGFR exon 20 insertion mutations, as well as in the Phase Ib FURTHER study for patients with EGFR PACC mutations.
The ADC Revolution in EGFR (搜索)-Targeted Therapy
The emergence of antibody-drug conjugates is further reshaping the competitive dynamics within the EGFR (搜索) NSCLC treatment landscape. Key ADC candidates in clinical development include PF-08046054 from Pfizer, patritumab deruxtecan from Daiichi Sankyo and AstraZeneca, sacituzumab tirumotecan (MK-2870) from Merck (搜索) and Kelun-Biotech, SYS6010 from CSPC Pharmaceutical, izalontamab brengitecan (BMS-986507) from Bristol-Myers Squibb, and telisotuzumab adizutecan from AbbVie (搜索).
Cetuximab: A Mature but Steady Presence
Beyond NSCLC, cetuximab (ERBITUX), an anti-EGFR (搜索) IgG1 monoclonal antibody, is projected to retain a steady but mature market presence in metastatic colorectal cancer (搜索) and head and neck cancers. In mCRC, cetuximab remains especially relevant in biomarker-driven settings, particularly among patients with EGFR-expressing and RAS wild-type tumors. Its utility is further strengthened through combination regimens with targeted agents such as encorafenib for BRAF V600E-mutated disease and adagrasib for KRAS G12C-mutated tumors. However, market expansion is expected to be moderate owing to product maturity, biosimilar competition, and the growing adoption of newer targeted therapies and immuno-oncology treatments.
Pipeline Depth and Future Outlook
The emerging pipeline encompasses a diverse range of therapeutic alternatives from companies including Black Diamond Therapeutics, BlossomHill Therapeutics, Scorpion Therapeutics, Pierre Fabre, BioNTech, Dragonfly Therapeutics, Merus, DualityBio, ORIC Pharmaceuticals, and BeOne Medicines, among others. In December 2025, the CHMP issued a positive opinion for AUMSEQA in adult NSCLC, covering first-line EGFR (搜索)-mutant disease and EGFR T790M-mediated acquired resistance.
As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the EGFR (搜索) inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth across the 7MM through 2036.